Crispr Theraptc (NASDAQ:CRSP) Earns Daily News Sentiment Rating of 0.16
News articles about Crispr Theraptc (NASDAQ:CRSP) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Crispr Theraptc earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.2931855833537 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Crispr Theraptc (CRSP) Releases Earnings Results, Beats Estimates By $0.06 EPS (americanbankingnews.com)
- CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update (finance.yahoo.com)
- Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster Sells 35,473 Shares (americanbankingnews.com)
- Crispr Theraptc (NASDAQ:CRSP) Insider Tyler Dylan-Hyde Sells 15,000 Shares (americanbankingnews.com)
- Insider Selling: Crispr Theraptc (NASDAQ:CRSP) Director Sells 50,477 Shares of Stock (americanbankingnews.com)
Shares of Crispr Theraptc (CRSP) opened at 19.22 on Friday. Crispr Theraptc has a 52-week low of $11.63 and a 52-week high of $25.00. The stock’s market cap is $766.78 million. The company has a 50-day moving average of $17.08 and a 200 day moving average of $17.49.
Crispr Theraptc (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.06. The firm had revenue of $3.60 million during the quarter, compared to the consensus estimate of $3.29 million. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 53.86%. The business’s quarterly revenue was up 350.0% on a year-over-year basis. Equities research analysts forecast that Crispr Theraptc will post ($2.48) EPS for the current fiscal year.
CRSP has been the subject of several research reports. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a research report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price target for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Finally, Cann initiated coverage on shares of Crispr Theraptc in a research report on Monday, July 17th. They issued a “market perform” rating for the company. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.92.
WARNING: “Crispr Theraptc (NASDAQ:CRSP) Earns Daily News Sentiment Rating of 0.16” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/13/crispr-theraptc-nasdaqcrsp-earns-daily-news-sentiment-rating-of-0-16.html.
In other Crispr Theraptc news, insider Tyler Dylan-Hyde sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $18.57, for a total value of $278,550.00. Following the sale, the insider now directly owns 167,727 shares in the company, valued at $3,114,690.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kurt Von Emster sold 35,473 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $18.63, for a total value of $660,861.99. The disclosure for this sale can be found here. Insiders sold 543,814 shares of company stock worth $9,232,047 over the last quarter. 39.98% of the stock is currently owned by company insiders.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.